Zacks Research Has Positive Estimate for BHC Q2 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for Bausch Health Companies in a research report issued on Tuesday, December 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.03 for the quarter, up from their previous forecast of $1.00. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.09 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.37 EPS and FY2026 earnings at $5.05 EPS.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the company earned $1.03 earnings per share. The company’s revenue for the quarter was up 12.2% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on BHC. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada lifted their target price on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $7.47 on Thursday. The company has a market capitalization of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46. The stock’s 50 day moving average price is $8.34 and its 200 day moving average price is $7.27.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Goldentree Asset Management LP grew its stake in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after purchasing an additional 6,958,717 shares during the last quarter. Bank of Montreal Can raised its position in shares of Bausch Health Companies by 234.0% in the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after buying an additional 2,685,675 shares during the last quarter. Maple Rock Capital Partners Inc. acquired a new stake in Bausch Health Companies during the third quarter worth about $16,850,000. Mackenzie Financial Corp raised its position in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after buying an additional 1,252,834 shares during the period. Finally, Clearline Capital LP acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $6,881,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.